BL 1827

Drug Profile

BL 1827

Alternative Names: Analgesic sublingual spray - Bioglan Pharma/CeNeS Pharmaceuticals; Opioid sublingual aerosol spray

Latest Information Update: 12 Aug 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bioglan Pharma [CEASED]
  • Class Analgesics
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer pain; Postoperative pain

Most Recent Events

  • 12 Aug 2002 The agent is available for licensing (
  • 12 Aug 2002 Discontinued - Phase-I for Cancer pain in United Kingdom (Sublingual)
  • 12 Aug 2002 Discontinued - Phase-I for Postoperative pain in United Kingdom (Sublingual)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top